Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOS-475 in Psoriasis Plaque Test
NCT04221906Phase 1Completed
- Sponsor
- Boston Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3183475 in plaque psoriasis (6 arms), sponsored by Boston Pharmaceuticals. Primary endpoints: Number of treatment-emergent adverse events at Day 19, Number of treatment-emergent application site reactions at Day 19 and 2 more. Started Jan 2020; status: completed.
02
Drugs
GSK3183475
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04221906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221906.